Immutep Limited Share Price Nasdaq
Stocks
IMMP
US45257L1089
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
21:00:00 22/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.2831 USD | -2.81% |
|
-14.29% | -90.10% |
| 09-17 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 09-15 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
| Market Cap | 60.42M 42.98M 37.54M 35.27M 32.18M 60.45M 4.11B 422M 163M 2.1B 161M 158M 6.77B | P/E 2027 * |
-2.41x | P/E 2028 * | -3.73x |
|---|---|---|---|---|---|
| Enterprise Value | 5.82M 4.14M 3.62M 3.4M 3.1M 5.82M 396M 40.7M 15.73M 202M 15.55M 15.21M 652M | EV / Sales 2027 * |
1.46x | EV / Sales 2028 * | 8.86x |
| Free-Float |
96.98% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| IMMP | Delayed | |
CBOE
| IMMP | Real-time | |
|
Deutsche Boerse AG
| YP1A | Delayed | |
|
Tradegate
| YP1A | Real-time | |
|
Börse Stuttgart
| YP1A | Delayed | |
|
Boerse Muenchen
| YP1A | Real-time |
| 1 day | -2.81% | ||
| 1 week | -14.50% | ||
| Current month | -22.65% | ||
| 1 month | -26.68% | ||
| 3 months | -24.35% | ||
| 6 months | -28.27% | ||
| Current year | -90.10% |
| 1 week | 0.28 |  | 0.34 |
| 1 month | 0.28 | | 0.4 |
| Current year | 0.28 | | 3.23 |
| 1 year | 0.28 | | 3.53 |
| 3 years | 0.28 | | 3.53 |
| 5 years | 0.28 | | 5 |
| 10 years | 0.28 | | 7.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 08/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 28/02/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 08/07/2014 |
Russell Howard
CHM | Chairman | 76 | 16/11/2017 |
Pete Meyers
BRD | Director/Board Member | 57 | 11/02/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.81% | -14.50% | - | - | 41.99M | |
| +2.55% | +5.35% | +3.61% | +32.02% | 46.68B | |
| +0.08% | +1.66% | +44.26% | +35.60% | 44.42B | |
| +0.05% | -5.97% | +342.95% | +532.74% | 41.32B | |
| +0.66% | +4.03% | +10.07% | +96.02% | 41.58B | |
| -1.60% | -0.17% | +9.73% | +43.63% | 30.14B | |
| +0.96% | +5.84% | +26.39% | +161.70% | 17.42B | |
| -0.01% | -10.32% | - | - | 15.6B | |
| +1.15% | +9.42% | +26.21% | +42.84% | 15.54B | |
| -1.08% | +24.08% | -12.52% | - | 14.08B | |
| Average | +0.12% | +3.39% | +56.34% | +134.93% | 29.64B | |
| Weighted average by Cap. | +0.53% | +1.94% | +70.50% | +142.88% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4M 2.85M 2.49M 2.33M 2.13M 4M 272M 27.96M 10.81M 139M 10.69M 10.45M 448M | 3M 2.13M 1.86M 1.75M 1.6M 3M 204M 20.97M 8.11M 104M 8.01M 7.84M 336M |
| Net income | -26.1M -18.56M -16.22M -15.23M -13.9M -26.11M -1.77B -182M -70.52M -907M -69.72M -68.19M -2.92B | -30.47M -21.68M -18.93M -17.79M -16.23M -30.49M -2.07B -213M -82.34M -1.06B -81.41M -79.62M -3.41B |
| Net Debt | -54.6M -38.84M -33.92M -31.87M -29.08M -54.62M -3.71B -382M -148M -1.9B -146M -143M -6.12B | -33.83M -24.07M -21.02M -19.75M -18.02M -33.85M -2.3B -237M -91.42M -1.18B -90.38M -88.39M -3.79B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/09/26 | US$0.2831 | -2.81% | 143,271 |
| 21/09/26 | US$0.2913 | +1.25% | 357,654 |
| 18/09/26 | US$0.2877 | -9.21% | 576,495 |
| 17/09/26 | US$0.3169 | -3.09% | 245,306 |
| 16/09/26 | US$0.3270 | -1.00% | 256,672 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IMM Stock
- IMMP Stock
Select your edition
All financial news and data tailored to specific country editions
